On January 5, 2026, the China–Korea Business Forum, jointly hosted by the China Council for the Promotion of International Trade (CCPIT) and the Korea Chamber of Commerce and Industry (KCCI), was grandly held at the Diaoyutai State Guesthouse in Beijing. Focusing on key themes such as manufacturing innovation, new consumer markets, and cooperation in the service sector, the forum explored future directions for China–Korea economic and trade collaboration. South Korean President Lee Jae-myung, who was paying a state visit to China, attended the opening ceremony and delivered a keynote address. More than 600 participants from both countries—including government officials, business leaders, and experts—were present at the event.
As a representative enterprise in China’s biomanufacturing sector, Bloomage was invited to attend the forum. Mr. Zou Songyan, Vice President of Business Operations, and Ms. Song Chunzi, General Manager of the company’s Korean subsidiary, participated in the event. During the forum, Mr. Zou delivered a keynote speech entitled “Biomanufacturing Driving Innovation and Upgrading in Consumer Industries,” elaborating on how biotechnology is reshaping the future of industries and sharing Bloomage’s strategic positioning in synthetic biology, as well as its achievements in international cooperation.
Biomanufacturing: A National Strategy and the Future of Industry
Mr. Zou noted that biomanufacturing, as a strategic high ground in the new wave of global technological revolution and industrial transformation, has been clearly identified in the CPC Central Committee’s proposals for the 15th Five-Year Plan as a future industry requiring forward-looking deployment. Biomanufacturing is now entering a critical stage of transition from technological breakthroughs to large-scale application.
By using renewable carbon resources such as carbon dioxide as raw materials and leveraging biological functions to achieve large-scale material synthesis, biomanufacturing offers core advantages including renewable inputs, clean and efficient processes, and sustainable industrial development. It provides a green alternative pathway for the industrial economy and helps reduce dependence on petroleum-based resources.
Bloomage: Redefining the Possibilities of Biomanufacturing
As a multinational biotechnology and biomanufacturing company driven by synthetic biology, Bloomage focuses on two major areas: glycobiology and cell biology. Relying on its globally leading synthetic biology pilot-scale transformation platform, the company is committed to translating advances in life sciences into life and health solutions in areas such as aging intervention and tissue regeneration. This platform also serves as foundational infrastructure for industry innovation, helping numerous scientific achievements overcome the “valley of death” between laboratory research and industrialization.
Through its biomanufacturing capabilities, Bloomage is promoting a fundamental shift of industries toward safer, greener, and more sustainable development. By applying synthetic biology–enabled biomanufacturing, the company is replacing traditional sources such as animal extraction, plant extraction, and petrochemical feedstocks. Taking ergothioneine—often referred to as a “longevity vitamin”—as an example, this amino acid derivative cannot be synthesized by the human body and is known for its antioxidant and anti-inflammatory properties. Bloomage has achieved large-scale production of high-quality ergothioneine with an ultra-high purity of 99%, overcoming the limitations of traditional extraction processes.
Notably, Bloomage is among the few companies worldwide that have established a comprehensive portfolio covering all major aging intervention biomarkers recognized in top-tier scientific journals. From salidroside and NMN to hyaluronic acid and chondroitin sulfate, the company has built a complete matrix of core substances centered on aging intervention, providing solid scientific support for life and health applications.
Deepening Roots in Korea: Opening a New Chapter of Cooperation
Leveraging its globally leading capabilities in large-scale biomanufacturing, engineering transformation efficiency, and a stable and reliable supply chain, Bloomage offers Korean innovative enterprises a solid foundation of high-quality and dependable support. This strong complementarity forms the cornerstone of bilateral cooperation. Since entering the Korean market in 2002 with hyaluronic acid raw materials, Bloomage has gradually expanded into pharmaceuticals, medical aesthetics, cosmetics, and functional foods. In 2023, the official establishment of Bloomage’s Korean subsidiary in Seoul marked a new phase in its operations in Korea.
Through more than two decades of sustained commitment, Bloomage has established deep, end-to-end partnerships in Korea with leading companies and research institutions across pharmaceuticals, medical aesthetics, cosmetics, and functional foods—covering the entire value chain from R&D and production to commercialization. Together, they have built a closely coordinated, mutually beneficial localized industrial ecosystem.
Looking Ahead
Looking ahead, Bloomage will continue to be driven by synthetic biology, deepen its focus on the life and health sector, and consistently promote industrial innovation and upgrading. The company aims to deliver higher-quality products and services to consumers worldwide, while working with industry partners to jointly build a sustainable biomanufacturing ecosystem.
